206 related articles for article (PubMed ID: 15029461)
1. Oestrogen-mediated regulation of somatostatin receptor expression in human breast cancer cell lines assessed with 99mTc-depreotide.
Van Den Bossche B; D'haeninck E; De Vos F; Dierckx RA; Van Belle S; Bracke M; Van de Wiele C
Eur J Nucl Med Mol Imaging; 2004 Jul; 31(7):1022-30. PubMed ID: 15029461
[TBL] [Abstract][Full Text] [Related]
2. The role of technetium-99m-labeled octreotide acetate scintigraphy in suspected breast cancer and correlates with expression of SSTR.
Wang F; Wang Z; Wu J; Qu W; Yao W; Zhao J; Liu Z
Nucl Med Biol; 2008 Aug; 35(6):665-71. PubMed ID: 18678351
[TBL] [Abstract][Full Text] [Related]
3. Early prediction of endocrine therapy effect in advanced breast cancer patients using 99mTc-depreotide scintigraphy.
Van Den Bossche B; Van Belle S; De Winter F; Signore A; Van de Wiele C
J Nucl Med; 2006 Jan; 47(1):6-13. PubMed ID: 16391181
[TBL] [Abstract][Full Text] [Related]
4. Quantitative assessment of 99mTc-depreotide uptake in patients with non-small-cell lung cancer: immunohistochemical correlations.
Herlin G; Kölbeck KG; Menzel PL; Svensson L; Aspelin P; Capitanio A; Axelsson R
Acta Radiol; 2009 Oct; 50(8):902-8. PubMed ID: 19707908
[TBL] [Abstract][Full Text] [Related]
5. Estrogen regulates somatostatin receptor subtype 2 messenger ribonucleic acid expression in human breast cancer cells.
Xu Y; Song J; Berelowitz M; Bruno JF
Endocrinology; 1996 Dec; 137(12):5634-40. PubMed ID: 8940394
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin receptor imaging of non-small cell lung cancer with 99mTc depreotide.
Menda Y; Kahn D
Semin Nucl Med; 2002 Apr; 32(2):92-6. PubMed ID: 11965604
[TBL] [Abstract][Full Text] [Related]
7. Differences in biodistribution between 99mTc-depreotide, 111In-DTPA-octreotide, and 177Lu-DOTA-Tyr3-octreotate in a small cell lung cancer animal model.
Schmitt A; Bernhardt P; Nilsson O; Ahlman H; Kölby L; Forssell-Aronsson E
Cancer Biother Radiopharm; 2005 Apr; 20(2):231-6. PubMed ID: 15869461
[TBL] [Abstract][Full Text] [Related]
8. Isolation, characterization, and biological evaluation of syn and anti diastereomers of [(99m)Tc]technetium depreotide: a somatostatin receptor binding tumor imaging agent.
Cyr JE; Pearson DA; Nelson CA; Lyons BA; Zheng Y; Bartis J; He J; Cantorias MV; Howell RC; Francesconi LC
J Med Chem; 2007 Sep; 50(18):4295-303. PubMed ID: 17691760
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis and staging of children's lymphoma using the technetium-labelled somatostatin analogue, 99mTc-depreotide.
Cholewinski W; Kowalczyk JR; Stefaniak B; Stefaniak J; Poniatowicz-Frasunek E; Tarkowska A
Eur J Nucl Med Mol Imaging; 2004 Jun; 31(6):820-4. PubMed ID: 14762697
[TBL] [Abstract][Full Text] [Related]
10. 99mTc depreotide scan compared with 99mTc-MDP bone scintigraphy for the detection of bone metastases and prediction of response to hormonal treatment in patients with breast cancer.
Van Den Bossche B; D'haeninck E; De Winter F; Van Belle S; Dierckx RA; Van De Wiele C
Nucl Med Commun; 2004 Aug; 25(8):787-92. PubMed ID: 15266172
[TBL] [Abstract][Full Text] [Related]
11. Imaging somatostatin receptor activity in patients with active thyroid eye disease using Tc-99m depreotide.
Doumas AS; Krassas GE; Kaltsas T; Pontikides N
Clin Nucl Med; 2003 May; 28(5):439-40. PubMed ID: 12702954
[No Abstract] [Full Text] [Related]
12. Accumulation of Tc-99m depreotide (NeoSpect) in axillary sweat glands.
Danielsson R; Bååth M; Kölbeck KG; Klominek J; Svensson L
Clin Nucl Med; 2003 Sep; 28(9):789-90. PubMed ID: 12973013
[TBL] [Abstract][Full Text] [Related]
13. 99mTc-depreotide in the evaluation of bone infection and inflammation.
Papathanasiou ND; Rondogianni PE; Pianou NK; Karampina PA; Vlontzou EA; Datseris IE
Nucl Med Commun; 2008 Mar; 29(3):239-46. PubMed ID: 18349794
[TBL] [Abstract][Full Text] [Related]
14. Experimental study of 99mTc-depreotide preparation and its affinity with A549 cell.
Xia W; Zhang X; Yu F; Wang P; Cai H; Hou R; Wang G; Yuan X; Lv Z
Front Biosci (Landmark Ed); 2011 Jun; 16(7):2527-39. PubMed ID: 21622193
[TBL] [Abstract][Full Text] [Related]
15. 99mTc-depreotide scintigraphy versus 18F-FDG-PET in the diagnosis of radioiodine-negative thyroid cancer.
Rodrigues M; Li S; Gabriel M; Heute D; Greifeneder M; Virgolini I
J Clin Endocrinol Metab; 2006 Oct; 91(10):3997-4000. PubMed ID: 16895961
[TBL] [Abstract][Full Text] [Related]
16. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors.
Gabriel M; Decristoforo C; Donnemiller E; Ulmer H; Watfah Rychlinski C; Mather SJ; Moncayo R
J Nucl Med; 2003 May; 44(5):708-16. PubMed ID: 12732671
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation of [99mTc/EDDA/tricine/HYNIC0, 1-Nal3, Thr8]-octreotide as a new analogue in the detection of somatostatin-receptor-positive tumors.
Gandomkar M; Najafi R; Shafiei M; Mazidi M; Ebrahimi SE
Nucl Med Biol; 2007 Aug; 34(6):651-7. PubMed ID: 17707805
[TBL] [Abstract][Full Text] [Related]
18. SSTR-Mediated Imaging in Breast Cancer: Is There a Role for Radiolabeled Somatostatin Receptor Antagonists?
Dalm SU; Haeck J; Doeswijk GN; de Blois E; de Jong M; van Deurzen CHM
J Nucl Med; 2017 Oct; 58(10):1609-1614. PubMed ID: 28450563
[TBL] [Abstract][Full Text] [Related]
19. Comparative evaluation of 99mTc-depreotide and 201Tl chloride single photon emission tomography in the characterization of pulmonary lesions.
Boundas D; Karatzas N; Moralidis E; Arsos G; Drevelengas A; Pistevou-Gompaki K; Karakatsanis C
Nucl Med Commun; 2007 Jul; 28(7):533-40. PubMed ID: 17538394
[TBL] [Abstract][Full Text] [Related]
20. Technetium-99m depreotide imaging by single photon emission tomography/low resolution computed tomography in malignant lymphomas: comparison with gallium-67 citrate.
Apostolopoulos DJ; Papandrianos NI; Symeonidis A; Spyridonidis T; Alexiou S; Zampakis P; Savvopoulos C; Vassilakos PJ; Matsouka P
Ann Nucl Med; 2010 Nov; 24(9):639-47. PubMed ID: 20799079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
